Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
PTC Financial Services CEO outlines four-pillar strategy amid board changes
30/09/2025
Anshul Saigal sees tailwinds for consumption, defence and renewables ahead of festive season
30/09/2025
How to explain US economy's 4% growth and no jobs
30/09/2025
Hindustan Zinc’s exposure to silver is underpriced, calls for re-rating, says Emkay Global
30/09/2025
Trump's peace plan : Perhaps impossible, but never more necessary
30/09/2025
Saudi Arabia is losing its appetite for oil : Here's what it means
30/09/2025
